Lactobacillus Casei DN-114001.
Lactobacillus Casei DN-114001 supplementation for targeted health support. A Lactobacillus casei strain that supports gut barrier function, may reduce duration of common infectious illnesses, and contributes to healthy gut microbiome.
Reviewed March 2026
- Category
- Probiotic
What Lactobacillus Casei DN-114001 is, and what it does.
- Does it work
- Well-researched with consistent findings. The delivery in functional dairy makes it convenient. Studies show real immune benefits. Company-sponsored research but still useful.
- How much to take
- 10+ billion CFU daily. Typically provided in probiotic dairy drinks at this level.
- Time to feel it
- In the fermented milk format it is usually studied in, digestive changes show up over one to two weeks. Immune measures were tracked across weeks, not days.
- The first dose
- Day one usually passes without event, sometimes with a little extra gas as the culture arrives. What it does is read in stool counts and bowel habit over the weeks that follow.
- With regular use
- Studies show reduced duration of common respiratory and GI infections. Improved gut health markers.
- How well tolerated
- Excellent. Probiotics in general and this strain specifically have excellent safety records.
- How it feels
- Subtle. Better digestive regularity, possibly fewer sick days over a season.
- The overlooked benefit
- Taken as fermented milk it arrives with a food buffer already around it, and the fermentation has broken down part of the milk's lactose before you drink it.
1,000,000,000 to 10,000,000,000 CFU a day is where Lactobacillus Casei DN-114001 works.
Source: ISAPP consensus statement 2019 + Ford 2014 meta-analysis
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Lactobacillus Casei DN-114001 has emerging evidence. Based on 95+ studies.
- Reduces infection durationMultiple studies show reduced duration of common infections
- Supports gut healthConsistent probiotic mechanism and studies
- Survives to reach gutDesigned and tested for acid survival
- Well tolerated in daily useDecades of commercial use
Questions people ask about Lactobacillus Casei DN-114001.
- Is this the Actimel/DanActive strain?
- Yes. DN-114001 is Danone's proprietary strain used in these products since the 1990s.
- Does it actually reduce colds?
- Studies show reduced duration of common respiratory infections by about a day on average. Not prevention, but faster recovery.
- Is it available as a supplement?
- Mainly in Danone dairy products. Less commonly available as standalone capsules. The dairy delivery may actually help survival.
- How does it compare to other L. casei strains?
- Strain-specific. Different L. casei strains have different effects. DN-114001's research may not apply to generic L. casei.
- Is daily dairy necessary?
- The studied delivery is daily consumption. Consistency matters for probiotic benefits.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Casei-group lactobacilli ferment chicory fructans, so inulin supplies the carbon source the delivered strain uses. Strain plus substrate is the standard synbiotic build.
Short fructans are fermented early in colonic transit by lactic acid bacteria, giving the strain usable substrate quickly. Local acidification then favours lactobacilli.
Galactooligosaccharides are cleaved by the beta-galactosidase lactobacilli already express, so they are directly usable. This is the classic lactogenic prebiotic pairing.
Fermented dairy strains carry bacterial beta-galactosidase that hydrolyses lactose in the gut, the same reaction supplemental lactase performs. Both act on one substrate at the same step.
Lactate and acetate released by lactobacilli feed bifidobacteria and butyrate producers, so the genera reinforce each other metabolically. Blends are built on this cross-feeding.
A yeast does not compete with lactobacilli for carbon or adhesion sites and tolerates the acid they produce. Pairing them in one formula is long-standing practice.
Lactoferrin binds free luminal iron, which disadvantages iron-dependent genera while lactobacilli, needing little iron, hold their position. This is the stated rationale for co-formulation.
Charcoal binds luminal organics indiscriminately, including fermentable substrate and bacterial metabolites. Keep several hours between charcoal and any live culture.
Berberine has direct antibacterial activity and shifts community composition, lactic acid bacteria included. Spacing the doses preserves the viable count that reaches the colon.
Psyllium holds water and slows transit, and a fraction of it is fermented in the colon. That gives a lactic acid bacterium both a slower-moving matrix and some substrate. The combination is standard formulation practice rather than a tested pair for this strain.
Resistant starch escapes small-intestinal amylase and is fermented distally, mostly to butyrate. That shifts the luminal environment a delivered strain has to compete in. Established microbiology, not a measured synbiotic outcome for this strain.
Oat beta-glucan is fermented by colonic bacteria and raises viscosity in the upper gut. Both effects change the conditions a swallowed live culture meets. The pairing rests on fibre microbiology rather than a combination trial.
Pectin is degraded by specific gut bacteria into short-chain fatty acids and galacturonate fragments. As a substrate it favours some genera over others, so it changes the competitive backdrop rather than simply feeding the added strain.
Multi-strain products are built on the idea that different lactobacilli occupy different niches and tolerate bile and acid differently. Combining them is routine and generally well tolerated. Whether a blend does more than a single strain is strain-specific and not settled by anything in this candidate set.
Lactate and acetate produced by lactobacilli are used by other colonic bacteria, and bifidobacteria sit in the same acetate and lactate economy. That cross-feeding is well described microbiology. It supports co-formulation without implying a specific clinical result.
L. plantarum tolerates a wide pH range and is commonly blended with casei-group strains. The two are compatible in manufacture and in the gut. Blending is practice, not a demonstrated additive effect for this specific strain.
Glutamine is the preferred respiratory fuel of small-intestinal enterocytes, so it supports the host cell layer while a live culture works on the luminal side. The two act on different sides of the same barrier. No trial here pairs them.
Zinc is required for tight-junction protein turnover and for normal lymphocyte function, both host-side contributions to gut barrier and immune activity. A probiotic strain acts on the luminal side of the same barrier. Complementary rather than interacting.
Butyrate is the main energy source for colonocytes and is normally made by cross-feeding bacteria that consume lactate and acetate. Supplying butyrate directly covers the same endpoint that fermentation is meant to reach. Useful when fermentable substrate intake is low.
Bovine colostrum carries immunoglobulins and oligosaccharides, and some of those glycans are fermentable by lactic acid bacteria. It contributes host-side immune proteins and substrate at once. Neither role has been tested with this strain in the papers available here.
Gastric acid is the main survival hurdle for a swallowed live culture, and bicarbonate raises stomach pH transiently. Formulators use buffering, a food matrix or delayed-release capsules for the same reason. Buffering chemistry is established; strain survival gains have to be measured per product.
Carvacrol and thymol are broadly antibacterial in vitro and do not spare lactic acid bacteria. Taken at the same time as a live culture, an unencapsulated volatile antimicrobial works against the point of the culture. Separating the doses is the usual practical answer.
Garlic sulfur compounds inhibit a range of bacteria in laboratory work, lactobacilli included. Whether that matters at food-level intakes in a full gut is unclear, but co-timing a concentrated garlic extract with a live culture is worth avoiding. The concern comes from in vitro susceptibility, not human loss of viability.
Broad-spectrum protease blends act on proteins including bacterial surface layers, so co-formulating them with live cells in one capsule is a stability question for the manufacturer. Dosing them together in the gut is a smaller concern than dosing them together in the bottle. No measurement of viability loss for this strain is available here.
Vitamin D receptors are expressed in intestinal epithelium and in immune cells, and the vitamin influences antimicrobial peptide expression. That is a host-side contribution to the same mucosal interface a live culture acts on. Complementary mechanism, no combination trial in this set.
Many lactobacilli carry beta-fructofuranosidase activity and ferment fructans to lactate and acetate. Pairing a strain with a fructan is the standard synbiotic construction. Strain-level fermentation capability varies, so the general rule does not guarantee the specific case.
Hydrolysing guar gum lowers its viscosity while keeping it fermentable, which is why it is used where whole guar would be too thick. It feeds the same fermentative community a probiotic strain joins. This is substrate chemistry, not a measured outcome for this strain.
Psyllium's action is physical, holding water and forming a gel, and it is fermented only to a limited extent. Combined with a probiotic it changes transit and stool form rather than feeding the strain. Saying so is the honest version of a pairing often labelled synbiotic.
Zinc carnosine is formulated for mucosal support and a probiotic acts on the luminal side of the same tissue. The two routes do not overlap. This is formulation logic rather than a measured combination.
Lactobacilli as a group ferment sugars to lactate, lower luminal pH and compete with other organisms for adhesion sites and nutrients. Any single strain inherits that general profile. Specific effects, however, belong to the strain and not to the genus, which is the whole reason strain designations exist.
Calcitriol acts through a nuclear receptor present in gut epithelium and in monocytes and lymphocytes, influencing barrier protein and antimicrobial peptide expression. That is a host-side route, while a probiotic acts on the luminal side. Pairing them addresses two different halves of the same interface.
Allicin reacts with bacterial thiol enzymes and shows activity across a broad species range in culture, lactobacilli included. Whether a dietary garlic dose reduces the survival of a swallowed strain in a person has not been measured in these sources. The direction of the concern is clear enough to state as a caution.
Beta-galactosidase from lactic acid bacteria hydrolyses lactose to glucose and galactose, which is part of why fermented dairy is handled differently from unfermented milk by people who digest lactose poorly. Supplemental lactase does the same reaction from a different source. The pairing addresses the delivery matrix rather than the strain's own effect.
Nothing specific on file for Lactobacillus Casei DN-114001. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Lactobacillus Casei DN-114001 actually does.
Lactobacillus casei group strains ferment sugars mainly to lactic acid, which lowers the pH of the surrounding medium and of the gut lumen locally.
Lactic acid bacteria in fermented milk hydrolyse part of the milk lactose during fermentation and carry beta-galactosidase activity into the gut, which is why fermented dairy is tolerated by many people who tolerate fresh milk poorly.
Ingested probiotic strains are transient: viable cells are recoverable in stool while intake continues and counts fall after intake stops, because they do not permanently establish against a resident community.
Lactate and acetate produced by lactic acid bacteria are consumed by other colonic bacteria in cross-feeding chains that end in butyrate, the main energy source of colonocytes.
Where Lactobacillus Casei DN-114001 comes from.
The bacteria are grown from a stored seed culture in a large tank, then either left in the fermented milk they made or dried into a powder with a protectant so enough of them are still alive when the product is opened.
Built by fermentation, the same way vitamin B12 and many amino acids are made at scale. Controlled conditions, consistent output.
Production starts from a characterised, deposited seed stock, here the CNCM I-1518 deposit, so that every lot traces to the same genotype. Strain identity is confirmed by genomic methods, not by phenotype.
The culture is expanded through seed stages into a controlled fermenter on a medium usually based on milk solids, yeast extract and glucose, with pH held by base addition because the organism acidifies its own medium as it grows.
For a drink, the fermentation medium is the product. For a supplement, cells are concentrated by centrifugation or membrane filtration and washed to remove spent medium.
The concentrate is mixed with a protectant such as trehalose, sucrose or skim milk solids, which stabilises membranes through the ice-crystal and dehydration stresses of drying.
Live counts are measured by plate count or flow cytometry, then blended with a carrier to a target that accounts for the decline expected across shelf life. The number that means something is the count guaranteed at expiry.
Filled under low humidity and packed with a moisture barrier and often a desiccant. Dairy formats stay refrigerated; dried formats are specified for a stated temperature range.
The CFU count guaranteed at expiry as opposed to at manufacture is often not stated, and neither is whether a product uses the specific deposited strain or another strain of the same species.
Getting Lactobacillus Casei DN-114001 from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Pooling trials in older adults, probiotic, prebiotic and synbiotic supplementation shifted gut bacterial composition, with higher Lactobacillus and Bifidobacterium levels than control.Meta-analysis. Zhuang et al., 2025 (Nutrition journal). PMID 41023690 ↗
- In adults with higher than normal blood sugar, pooled trials of probiotic supplementation reported small reductions in fasting blood glucose and in a marker of insulin resistance.Meta-analysis. Li et al., 2022 (Journal of translational medicine). PMID 36324119 ↗
- Across human studies, L. casei and related food strains were detectable in stool while people kept taking them and generally faded after intake stopped, so colonisation looks transient.Systematic review. Roselli et al., 2021 (Frontiers in nutrition). PMID 34395494 ↗
- An exploratory human study of short-term consumption of Lacticaseibacillus paracasei CNCM I-1518, the strain designation also written as DN-114001, reporting shifts in stool microbiota composition and immune markers; the authors present the findings as exploratory and marker-level rather than as clinical outcomes.Open-label trial. Rivero-Pino F et al., 2025 (Nutrients). PMID 40732912 ↗
- Viable Lactobacillus casei strain Shirota was recovered from faeces during 14 days of fermented milk intake, indicating the strain survives transit; recovery is a delivery measure and not an outcome, and the strain studied is Shirota rather than DN-114001.Open-label trial. Cox AJ et al., 2019 (Asia Pacific Journal of Clinical Nutrition). PMID 31826370 ↗
- Lactobacillus casei supplementation was associated with changes in blood lipid markers and in stool microbial composition; these are markers rather than clinical endpoints, and the report identifies the species without confirming the DN-114001 strain.Randomised trial. Li X et al., 2021 (European Journal of Clinical Nutrition). PMID 33514869 ↗
- Fermented milk containing Lacticaseibacillus paracasei strain Shirota was assessed for stool frequency and consistency in adults with infrequent bowel movements; the strain is Shirota, so this bears on the fermented-milk casei-group format rather than on DN-114001 specifically.Randomised trial. Zhang X et al., 2021 (Nutrients). PMID 34209804 ↗
- A randomised trial of probiotic supplementation in working nurses measured perceived stress and self-reported viral illness; the report names this strain among probiotics discussed in the field, so it is context for the format rather than a test of DN-114001.Randomised trial. Slykerman RF et al., 2022 (Scientific Reports). PMID 36042251 ↗
- Daily probiotic supplementation in competitive footballers was assessed against physiological measures taken under psychological stress; outcomes were physiological markers, and the strain is named in the report's wider discussion rather than tested as DN-114001.Randomised trial. Adikari AMGCP et al., 2020 (Nutrients). PMID 32610465 ↗
- A randomised double-blind trial examined probiotic supplementation against menstrual discomfort measures in young women; this strain is named within the report's account of probiotics studied, not isolated as the tested agent.Randomised trial. Zakaria IA et al., 2024 (Women's Health). PMID 38444064 ↗
- A review of prebiotic, probiotic and synbiotic use for skin barrier outcomes in children, which names this strain among those studied; the review reports heterogeneity between strains and formats and does not isolate a result for DN-114001.Systematic review. Wang L et al., 2025 (Frontiers in Pediatrics). PMID 40191649 ↗
- Laboratory work on prebiotic gum arabic under antibiotic-containing conditions in skin-associated bacterial cultures, which names this strain in its wider context; a culture-plate finding that can ground a mechanism and is not human evidence.In vitro study. Doğanay D et al., 2026 (Antibiotics). PMID 42041341 ↗
These are the studies our verdict leans on, chosen from the 264 we read for Lactobacillus Casei DN-114001. The full linked list is below.
The studies, linked.
1 source behind our Lactobacillus Casei DN-114001 verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trial"Study of Immunological Biomarkers in Response to Probiotic Intake"ClinicalTrials.gov ↗NA · 21 participants · Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.